Skip to main content
Signal8

New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention

$GILDPress releaseNov 6, 2026, 12:16 PM ETRead the release

Gilead announced Phase 2 PURPOSE 5 results showing twice-yearly injectable lenacapavir achieved 85.6% one-year PrEP persistence versus 46.3% for daily oral F/TDF (p<0.0001). Zero HIV acquisitions occurred among lenacapavir recipients over the 52-week study period, versus one acquisition in the F/TDF arm, with a safety profile consistent with prior studies.

Key figures

Drug Name
lenacapavir
Phase Of Trial
Phase 2
P value
p<0.0001
Serious aes ftdf
3.4%
Participants enrolled
267
Ftdf persistence week52
46.3% (37/80)
Serious aes lenacapavir
3.9%
Hiv acquisitions ftdf arm
1
Lenacapavir persistence week52
85.6% (154/180)
Hiv acquisitions lenacapavir arm
0

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.